ZL 2102

Drug Profile

ZL 2102

Alternative Names: ZL2102

Latest Information Update: 19 Mar 2015

Price : $50

At a glance

  • Originator Sanofi
  • Developer ZAI Lab
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 17 Mar 2015 Phase-I clinical trials in Asthma (In volunteers) and Chronic obstructive pulmonary disease (In volunteers) in Australia (unspecified route)
  • 12 Aug 2014 ZL 2102 licensed to Zai Lab worldwide
  • 12 Aug 2014 Preclinical trials in Asthma and Chronic obstructive pulmonary disease in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top